Locations:
Search
New insights on effectiveness in patients previously treated with other anti-VEGF drugs
Switching medications may decrease treatment burden and macular fluid
Advanced OCT features may help individualize treatment intervals
53% of participants didn’t need anti-VEGF for six months or longer
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Faricimab every 16 weeks offers similar benefits as aflibercept every eight weeks
Patients with diabetic eye disease are most affected
Studies evaluate patients who missed treatments for diabetic macular edema and neovascular age-related macular degeneration
Greater durability of action also allows spacing of doses
Advertisement
Advertisement